Finance1 min read

After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?

By · Published by Everything Blog

In short

In the 126-patient study, the experimental therapy demonstrated a median overall survival of 24 months compared to 14.7 months for standard care, cutting the risk of death by 41%. The WT1-targeting immunotherapeutic vaccine was generally well tolerated with no new safety issues identified during testing. Sellas now plans to meet with the US Food and Drug Administration to pursue an accelerated pathway and submit a Biologics License Application in the first half of 2027. Meanwhile, the company is managing potential dilution from an underwritten public offering of up to $172.5 million managed by J.P. Morgan and TD Cowen.

Key points

  • Clinical efficacy data from the late-stage trial supports plans to target an accelerated…: Clinical efficacy data from the late-stage trial supports plans to target an accelerated Biologics License Application filing by early 2027.
  • Sustained investor demand has overshadowed dilution risks stemming from the company's con…: Sustained investor demand has overshadowed dilution risks stemming from the company's concurrent multi-million dollar equity financing.
  • Alliance Global Partners highlighted the findings as clinically meaningful, reinforcing o…: Alliance Global Partners highlighted the findings as clinically meaningful, reinforcing optimism for potential expedited regulatory approval.

Sources checked by our analysis pipeline: 1

Shares of US-based biotechnology company Sellas Life Sciences extended their spectacular rally on Wednesday, November 18, rising another 5% after soaring nearly 156% in the previous session.

The stock has come under investors' radar following a major breakthrough in a late-stage clinical trial of its experimental cancer vaccine, which demonstrated a significant improvement in survival outcomes among patients with an aggressive form of blood cancer.

The sharp rally came after the company announced positive results from its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an investigational immunotherapeutic cancer vaccine designed to treat acute myeloid leukaemia (AML).

The results marked a significant milestone for the company, with the trial meeting its primary endpoint of overall survival. Sellas said the treatment reduced the risk of death by 41% compared with the best available treatment, with a hazard ratio of 0.59 and a statistically significant p-value of 0.035, as per the company's press release.

The company said that the 126-patient study showed that patients receiving GPS achieved median overall survival of 24 months, compared with 14.7 months among those receiving the best…

Finance